Medivation, Astellas Pharma conclude patient recruitment in Phase 3 Affirm study
Medivation and Astellas Pharma said that the trial is evaluating 160mg/day of MDV3100 versus placebo. Conducted at sites in the US, Canada, Europe, Australia, South America and South
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.